As a third-generation EGFR tyrosine kinase inhibitor, furmonertinib has established its role as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer, demonstrating a generally favorable safety profile. This evidence concerns the gene EGFR and non-small cell lung carcinoma.